Thought Leader Select Announces New KOL Identification and Profiling Projects in Oncology, Neurology

Thought Leader Select is pleased to announce a series of key opinion leader (KOL) identification and profiling projects to support multiple therapeutic areas for a top five global biopharmaceutical company.

In these research assessments, Thought Leader Select will identify and profile leading medical experts in neurology and oncology to support drug development initiatives in various cancers and neurological disorders. The oncologists and neurologists will represent many of the leading physicians at top medical centers of excellence throughout Canada.

Thought Leader Select will use its validated, objective deep profiling methodology to assess the skills and experience of the thought leaders in oncology and neurology in multiple research categories, including their areas of expertise, medical/scientific journal publishing history, and participation in basic and clinical research.  The company’s research group is comprised of subject-matter experts in medicine, with decades of experience working in medical research and clinical settings in the United States, Canada, Australia, and Africa.

The project will yield over 100 physicians who may advise the company on its development efforts in the treatment of cancers and neurological diseases. Typically, key opinion leaders serve on scientific advisory boards and participate in late-stage clinical trials to monitor the effectiveness of new drugs in larger patient populations.

“We are honored that this company has chosen to partner with us again to use effective solutions to identify and profile key opinion leaders,” stated Neil Mellor, a global business development consultant at Thought Leader Select. “It is a privilege to assist them in finding medical experts to collaborate with them on new treatments for patients suffering from various cancers and debilitating neurological conditions.  This company truly puts patients first, as evidenced by its previous success in developing key treatments in a number of therapeutic areas and its continued commitment in oncology and neurology.”

More Posts

The MSL Playbook for Creating Value

By Mark Schoeman, General Manager Prior to and over the course of the pandemic, assessments have shown that scores for MSL teams have remained consistent.


Send Us A Message